Popular terms

[SEARCH]

Antagonist topics
Antagonist
Recurrence
Proliferative Disorder
Proliferative
Antibodies
Progesterone
Dicyclomine
Scopolamine
Extracellular
Pharmaceutically Acceptable Salt
Metalloprotein
Nucleic Acids
Polynucleotide
Nucleic Acid
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antagonist patents



      
           
This page is updated frequently with new Antagonist-related patent applications. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds. RSS updates for this page: Antagonist RSS RSS



Date/App# patent app List of recent Antagonist-related patents
07/30/15
20150211073 
 Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist patent thumbnailnew patent Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist
Use of at least an mdm2 gene panel, preferably a four gene mdm2 gene panel, as a biomarker for predicting the response to a mdm2 antagonist.. .
Hoffmann-la Roche Inc.


07/30/15
20150210772 
 Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody patent thumbnailnew patent Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
The present invention describes combination treatment comprising a pd-1 axis binding antagonist and an anti-cd20 antibody and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.. .
Genentech, Inc.


07/30/15
20150210767 
 Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists patent thumbnailnew patent Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
The invention relates to storage-stable anti-tnfr1 antibody single variable domains (dabs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-tnfr1 polypeptides, antibody single variable domains (dabs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or copd, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the gi tract of a patient..
Glaxo Group Limited


07/30/15
20150210689 
 Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation patent thumbnailnew patent Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
Compounds, processes for their preparation, pharmaceutical compositions containing such compounds and their use in treating therapeutic conditions, in particular conditions mediated by the action of ligands on the fp, dp, ep1, ep4, ip, dp1, fp and tp prostaglandin (pg) receptors thereby providing a general anti-inflammatory response.. .
Allergan, Inc.


07/30/15
20150210649 
 Process for preparation of androgen receptor antagonist patent thumbnailnew patent Process for preparation of androgen receptor antagonist
The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist.
Cadila Healthcare Limited


07/30/15
20150209426 
 Treatment of cancer patent thumbnailnew patent Treatment of cancer
A method for treating breast cancer with an insulin-like growth factor (igf) receptor antagonist in combination with exemestane and everolimus.. .
Boehringer Ingelheim International Gmbh


07/30/15
20150209359 
 Combination therapies and methods of use thereof for treating cancer patent thumbnailnew patent Combination therapies and methods of use thereof for treating cancer
Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone.
Massachusetts Institute Of Technology


07/30/15
20150209353 
 Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome patent thumbnailnew patent Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
Methods for treating down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-ht6) receptor antagonists are provided for improving the cognition of a down syndrome patient..
The University Of Utah Research Foundation


07/30/15
20150209348 
 Histamine 4 receptor partial agonists, inverse agonists or antagonists for use in treating non-autoimmune uveitis patent thumbnailnew patent Histamine 4 receptor partial agonists, inverse agonists or antagonists for use in treating non-autoimmune uveitis
The invention provides a compound which is a histamine 4 receptor antagonist, partial agonist or inverse agonist, for use in the treatment of non-autoimmune uveitis. The compound preferably has a structural core comprising a substituted pyrimidine group, such as an aminopyrimidine, diaminopyrimidine or triaminopyrimidine group, a thienopyrimidine, a furopyrimidine, a benzimidazole, an aryl or heteroaryl-fused pyrimidine, an indole, a bicyclic heteroaryl-substituted imidazole or a quinazoline group..
Ucl Business Plc


07/30/15
20150209311 
 (r,r) formoterol in combination with other pharmacological agents patent thumbnailnew patent (r,r) formoterol in combination with other pharmacological agents
This invention related to methods of treating, preventing and managing various pulmonary diseases or disorders using stereomerically pure (r,r)-formoterol in combination with other pharmacological agents such as leukotriene inhibitors and neurokinin receptor antagonists. Pharmaceutical compositions comprising (r,r)-formoterol and other pharmacological agents are also disclosed..
Sunovion Pharmaceuticals Inc.


07/23/15
20150204892 

Methods and compositions for diagnosis and prognosis of renal injury and renal failure


The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of tumor necrosis factor receptor superfamily member 10b, cadherin-16, caspase-9, bcl2 antagonist of cell death, caspase-1, cadherin-1, poly [adp-ribose] polymerase 1, cyclin-dependent kinase inhibitor 1, cadherin-5, myoglobin, apolipoprotein a-ii, mucin-16, carcinoembryonic antigen-related cell adhesion molecule 5, and cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries..
Astute Medical, Inc.


07/23/15
20150203819 

Production of red blood cells and platelets from stem cells


This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (mep), comprising differentiating a mep precursor cell into a mep in culture in the presence of an aryl hydrocarbon receptor (ahr) modulator. In some embodiments the ahr modulator is an ahr antagonist.
Trustees Of Boston University


07/23/15
20150203585 

Use of dr6 and p75 antagonists to promote survival of cells of the nervous system


The present invention relates to death receptor-6 (dr6) proteins which are members of the tumor necrosis factor (tnf) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for dr6.
Biogen Idec Ma Inc.


07/23/15
20150203496 

Aliphatic spirolactam cgrp receptor antagonists


The present invention is directed to aliphatic spirolactam derivatives which are antagonists of cgrp receptors and useful in the treatment or prevention of diseases in which cgrp is involved, such as migraine. The invention is also directed to pharmaceutical\compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which cgrp is involved..
Merck Sharp & Dohme Corp.


07/23/15
20150203452 

Piperidinium quaternary salts


There are described new 1-alkyl-1-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halides and pharmaceutical compositions comprising a 1-alkyl-1-methyl-4-[(2,2-diphenyl-2-propoxy)acetoxy]piperidinium halide as an active ingredient. These products are non-selective muscarinic acetylcholine receptor antagonists acting in the periphery and not in the brain..
Chase Pharmaceuticals Corporation


07/23/15
20150202297 

Dry powder inhalers comprising a carrier other than lactose and a ternary component


This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose, and its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (copd) and other obstructive airways diseases. More particularly, the invention relates to pharmaceutical composition for inhalation further comprising a ternary component.
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi


07/23/15
20150202289 

Combination therapy for the treatment of ocular neovascular disorders


The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a pdgf antagonist and a vegf antagonist to the patient. The invention also features a pharmaceutical composition containing a pdgf antagonist and a vegf antagonist for the treatment or prevention of a neovascular disorder..
Ophthotech Corporation


07/23/15
20150202288 

Combination therapy for the treatment of ocular neovascular disorders


The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a pdgf antagonist and a vegf antagonist to the patient. The invention also features a pharmaceutical composition containing a pdgf antagonist and a vegf antagonist for the treatment or prevention of a neovascular disorder..
Ophthotech Corporation


07/23/15
20150202259 

Targeted oesophageal administration of zn-alpha2-glycoproteins (zag), methods and formulations thereof


The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
Aston University


07/23/15
20150202213 

Combinations comprising antimuscarinic agents and corticosteroids


Combinations comprising (a) a corticosteroid and (b) an antagonist of m3 muscarinic receptors which is 3(r)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion x, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.. .

07/23/15
20150202199 

Treatments for depression and other diseases with a low dose agent


The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (adhd), restless leg syndrome (rls), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists..
Pharmorx Therapeutics, Inc.


07/23/15
20150202148 

Dry powder inhalers comprising a carrier other than lactose


This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose, and its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (copd) and other obstructive airways diseases. In addition, the present invention relates to novel pharmaceutical composition for inhalation based on combinations of long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, corticosteroids or a combination of two or more of them..
Arven Llac Sanayi Ve Ticaret Anonim Sirketi


07/16/15
20150197574 

Use of transferrin receptor antagonist for the treatment of thalassemia


The present disclosure relates to antagonists of transferrin receptor and compositions and methods of use of said antagonists for treating pathological disorders such as thalassemia disorders. .
Universite Paris Diderot - Paris 7


07/16/15
20150197566 

Polynucleotides encoding antagonists of il-17a, il-17f, and il-23p19


The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of il-17a, il-17f, and il-23. Antagonists include antibodies and antibody fragments that bind il-23 and that bind il-17a or il-17f, such as antibodies that are cross-reactive for il-17a and il-17f.
Zymogenetics, Inc.


07/16/15
20150197563 

Notch binding agents and antagonists and methods of use thereof


The present invention relates to notch-binding agents and notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human notch receptor, such as notch2 and/or notch3, and inhibit tumor growth.
Oncomed Pharmaceuticals, Inc.


07/16/15
20150197560 

Humanized anti-beta7 antagonists and uses therefor


The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.. .
Genentech, Inc.


07/16/15
20150197521 

Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor


The present invention provides compounds of formula (i): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of p2y1 receptor which may be used as medicaments..
Bristol-myers Squibb Company


07/16/15
20150197506 

Novel benzopyran compounds, compositions and uses thereof


Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are op-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3r)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2h-chromen-7-ol, and op-1074, which is (2s)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3r)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2h-chromen-7-ol. Op-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode.
Olema Pharmaceuticals, Inc.


07/16/15
20150197490 

Crystalline polymorphic forms of an antidiabetic compound


This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included..

07/09/15
20150191540 

Preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient


A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising an interleukin-6 (il-6) antagonist, for example an antibody directed against il-6 receptor, an antibody directed against il-6, an antibody directed against gp130, and the like.. .
Chugai Seiyaku Kabushiki Kaisha


07/09/15
20150191487 

Tetrazole-substituted arylamides as p2x3 and p2x2/3 antagonists


Or a pharmaceutically acceptable salt thereof, wherein, r1 is optionally substituted tetrazolyl, r2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and r3, r4, r5 and r6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the p2x3 and/or a p2x2/3 receptor antagonist and methods of making the compounds..

07/09/15
20150191452 

Selective nr2b antagonists


The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the nr2b receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company


07/09/15
20150191435 

Dual-acting imidazole antihypertensive agents


Wherein: ar, r, r2-3, x, and r5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have at1 receptor antagonist activity and neprilysin inhibition activity.

07/09/15
20150191431 

N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products


The invention relates to n-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides, intermediates and methods for their production, use thereof for treating and/or preventing diseases and use thereof for producing medicinal products and use thereof for treating and/or preventing diseases, especially of hyperproliferative diseases.. .
Bayer Pharma Aktiengesellschaft


07/09/15
20150191426 

Methods and compositions for oral delivery of fts


Disclosed are oral dosage forms containing a ras antagonist including fts and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the ras antagonists.. .
Concordia Pharmaceuticals, Inc.


07/09/15
20150190523 

Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation


A pharmaceutical composition comprising a phosphatidylcholine-based opioid receptor antagonist formulation, as well as methods of their use and methods of their preparation are provided herein. Such pharmaceutical composition may be used for treating and preventing opioid-induced side effects in patients, and may be provided to chronic opioid users as well..
The University Of Chicago


07/09/15
20150190506 

Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists


The invention provides compositions and methods for treating cancers. The method comprises administering a pd-1 axis binding antagonist and an ox40 binding agonist..
Genentech, Inc.


07/09/15
20150190472 

Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ace2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation


The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogues, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-ii converting enzyme (ace2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide.
Universidad De Chile


07/09/15
20150190402 

Solid dosage formulations of an orexin receptor antagonists


The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant. The concentration-enhancing polymer is a polymer that forms an amorphous dispersion with suvorexant, that is insoluble or almost completely insoluble in water by (a) dissolving the suvorexant or (b) interacting with the suvorexant in such a way that the suvorexant does not form crystals or crystalline domains in the polymer.
Merck Sharp & Dohme Corp.


07/09/15
20150190399 

New differential-release pharmaceutical composition containing three active principles


This invention relates to a differential release formulation containing an angiotensin-ii receptor antagonist, a calcium channel blocker and a diuretic, wherein the said pharmaceutical composition allows the sequential administration of the active principles in a single dose based on the treatment needs.. .
Landsteiner Scientific S.a. De C.v.


07/02/15
20150184247 

Gene expression profiles associated with metastatic breast cancer


A gain-of-function retroviral cdna screen reveals that coco, a secreted antagonist of tgf-β ligands, induces solitary mammary carcinoma cells, which have disseminated to others sites and undergone an extended period of dormancy, to exit from dormancy at lung metastatic sites. Evidence indicates that coco awakens tumor progenitor cells that have extravasated into the lung by inhibiting stroma-derived bone morphogenetic proteins (bmp).
Memorial Sloan-kettering Cancer Center


07/02/15
20150183872 

Antagonist antibodies against ephb3


Ephb3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an ephb3-related disease or disorder.. .
Xoma Technology Ltd.


07/02/15
20150183847 

Protein and protein conjugate for diabetes treatment, and applications thereof


The present invention relates to the field of biopharmaceutics, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is glp-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a gip receptor binding polypeptide or an analogue thereof.
Adda Biotech Inc.


07/02/15
20150183845 

Antagonists of activin-actriia and uses for increasing red blood cell levels


In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.. .
Acceleron Pharma, Inc.


07/02/15
20150183812 

Pyrimidine compound and medical use thereof


Wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like.

07/02/15
20150183800 

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto


Wherein r1a, r1b, r1c, r1d, r2, r2a, and a are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof..

07/02/15
20150183768 

Heteroaromatic methyl cyclic amine derivative


A heteroaromatic methyl cyclic amine derivative represented by formula (ia) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of an orexin (ox) receptor antagonist activity.. .
Taisho Pharmaceutical Co., Ltd.


07/02/15
20150182746 

Device for increasing microcirculation


A method and device for increasing microcirculation in the lower limb are described. The device includes a means for immobilising the limb, for example a plaster cast, and an electrical stimulation device, which applies electrical stimulation to opposed leg muscles such that antagonistic and agonistic muscle groups contract near simultaneously, resulting in near isometric contraction.
Sky Medical Technology Ltd.


07/02/15
20150182623 

Compositions comprising an anti-pdgf aptamer and a vegf antagonist


The present invention is directed to compositions comprising an anti-pdgf aptamer and a vegf antagonist. In certain embodiments, the compositions of the invention are useful for treating or preventing an ophthalmological disease..
Ophthotech Corporation


07/02/15
20150182583 

Methods for treatment and prevention of tauopathies by inhibiting endothelin receptors


Compositions and methods of treatment of tauopathies are provided. In some embodiments, an antagonist of endothclin receptor a (eta) and endothelin receptor b (etb) may be administered to a subject to reduce tau production or accumulation, e.g., in astrocytes.
Board Of Regents, The University Of Texas System


07/02/15
20150182533 

5-ht3 receptor antagonists


The present invention provides a method of treating nicotine addiction comprising administering a 5-ht3 receptor antagonists of formula (i):. .
Takeda Pharmaceutical Company Limited


07/02/15
20150182520 

Compositions and methods for treatment


The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
Sarcode Bioscience Inc.


07/02/15
20150182504 

Methods of targeting pten mutant diseases and compositions therefor


Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a pten gene mutation and/or a pi3k gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a plk4 antagonist..
University Health Network


07/02/15
20150182503 

Mineralocorticoid receptor antagonists


The present invention is directed to compounds of the formula i: as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases. The invention furthermore relates to specific diastereomers and enantiomers of the compounds, to processes for preparing compounds of the formula i, to their potential use for the therapy and prophylaxis of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula i..
Merck Sharp & Dohme Corp.


07/02/15
20150182467 

Tamper-resistant oral opioid agonist formulations


Methods of decreasing abuse potentials of oral opioid dosage forms are described. In the methods, an opioid antagonist in a substantially non-releasable form is included in oral dosage forms comprising an opioid agonist.
Purdue Pharma L.p.


06/25/15
20150175712 

Antagonist to an enzyme and/or a metabolite of the kynurenine pathway


The present invention relates to a modulator of an enzyme and/or a metabolite of the kynurenine pathway (fig. 18)..
Immusmol Sas


06/25/15
20150175710 

Alpha-enolase specific antibodies and use in immune diseases


A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against eno1. The antagonist binds eno1 and inhibits eno1 plasminogen receptor activity.
Development Center For Biotechnology


06/25/15
20150175695 

Rac1 inhibitors for the treatment of alport glomerular disease


The present invention provides methods of treating alport syndrome in a subject by the administration of an agent that can blocks the activation of rac1/cdc42 members of the rho family of small gtpases. Such agents include, but are not limited to, the endothelin receptor antagonists such as bosentan and letairis and neutralizing antibodies to endothelin-1.
Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital


06/25/15
20150175692 

Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders


The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17a. The disclosure more specifically relates to specific antibodies and proteins that are il-17a antagonists (inhibit the activities of il-17a and il-17af) and are capable of inhibiting il-17a induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo.
Novartis Ag


06/25/15
20150175665 

Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal


There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide, pharmaceutical compositions containing said compounds, and the use of said compounds as gip-receptor agonists or antagonists for treatment of gip-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.. .
Ipsen Pharma S.a.s.


06/25/15
20150175644 

Mannose derivatives as antagonists of bacterial adhesion


Compounds of the formula (i) wherein n is 0, 1 or 2, r1 is aryl, heteroaryl or heterocyclyl, and r2 and r3 are hydrogen or a substituent as described in the specification, are useful for the prevention and treatment of bacterial infections, in particular of urinary infections caused by e. Coli..
University Of Basel


06/25/15
20150175581 

Compositions and methods for treatment


The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
Sarcode Bioscience Inc.


06/25/15
20150175580 

Compositions and methods for treatment


The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
Sarcode Bioscience Inc.


06/25/15
20150175579 

Compositions and methods for treatment


The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
Sarcode Bioscience Inc.


06/25/15
20150175578 

Compositions and methods for treatment


The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
Sarcode Bioscience Inc.


06/25/15
20150175577 

Compositions and methods for treatment


The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
Sarcode Bioscience Inc.


06/25/15
20150175570 

Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor


The invention relates to compounds of the formula r1 is selected from the group consisting of hydrogen, linear c1-c3 alkyl and fluorinated linear c1-c3 alkyl; r2 is hydrogen or methyl; r3 is selected from the group consisting of hydrogen, halogen, c1-c2-alkyl, fluorinated c1-c2-alkyl, c1-c2-alkoxy and fluorinated c1-c2-alkoxy, r4 is c1-c2-alkyl or fluorinated c1-c2-alkyl; n is 0, 1 or 2, and the physiologically tolerated salts of these compounds and the n-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula i and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine d3 receptor antagonists or dopamine d3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula i to a subject in need thereof..
Abbvie Deutschland Gmbh & Co. Kg


06/25/15
20150174143 

Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity


Prodrugs of steroidal c-17 benzoazoles, pyrimidinoazoles (az-abenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at a ring portion of the abc ring structure of the steroid.
University Of Maryland, Baltimore


06/25/15
20150174122 

Methods for treating eye disorders using opioid receptor antagonists


A method comprising: topically administering to eye/s of a subject in need of treatment for a disorder selected from the group consisting of pterygium, pinguecula and pink eye a composition comprising an effective amount of an active ingredient selected from the group consisting of naltrexone, naloxone or nalmefene or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.. .
Remedeye Inc.


06/25/15
20150174119 

Compositions and methods for treatment


The present invention provides compounds and methods for the treatment of lfa-1 mediated diseases. In particular, lfa-1 antagonists are described herein and these antagonists are used in the treatment of lfa-1 mediated diseases.
Sarcode Bioscience Inc.


06/25/15
20150174064 

Compositions comprising muscarinic receptor antagonist and glucose anhydrous


The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices..
Arven Iiac Sanayi Ve Ticaret A.s.


06/25/15
20150174061 

Intranasal naloxone compositions and methods of making and using same


Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of naloxone for the treatment of, for example, opioid overdose in an individual in need thereof.
Antiop, Inc.


06/25/15
20150173918 

Peripheral neural interface via nerve regeneration to distal tissues


At least partial function of a human limb is restored by surgically removing at least a portion of an injured or diseased human limb from a surgical site of an individual and transplanting a selected muscle into the remaining biological body of the individual, followed by contacting the transplanted selected muscle, or an associated nerve, with an electrode, to thereby control a device, such as a prosthetic limb, linked to the electrode. Simulating proprioceptive sensory feedback from a device includes mechanically linking at least one pair of agonist and antagonist muscles, wherein a nerve innervates each muscle, and supporting each pair with a support, whereby contraction of the agonist muscle of each pair will cause extension of the paired antagonist muscle.
Massachusetts Institute Of Technology


06/18/15
20150167090 

Diagnosis and prognosis of severity of autism spectrum disorders


Methods of predicting the level of symptom severity in individuals with autism spectrum disorders (asd) that may include autism disorder, asperger syndrome, and pervasive developmental disorder not otherwise specified. Therapeutic methods of delivering duf1220 domain con1 subtype domain protein products or fragments or mimetics thereof or antagonists thereof to treat asd or ameliorate symptoms of asd in an individual..

06/18/15
20150166642 

Methods and compositions for peroxisome proliferator-activated receptor gamma coactivator-1alpha (pgc1alpha) as a target of circulating tumor cells


The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing a metastatic as disease that results in increased mitochondrial respiration and/or biogenesis. In particular, the methods and compositions include treatment of metastatic diseases such as breast cancer using an antagonist of mitochondrial respiration such as a pgc1α antagonist..
Beth Isreal Deaconess Medical Center, Inc.


06/18/15
20150166634 

Soluble tnf receptors and their use in treatment of disease


The present invention relates to tumor necrosis factor (tnf) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (tnfrs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to tnf and prevent tnf from signaling to cells.
Roche Innovation Center Copenhagen A/s


06/18/15
20150166630 

Btnl3 proteins, nucleic acids, and antibodies and uses thereof


The invention provides novel btnl3 proteins, including multimers, fragments, fusion proteins, and variants. In addition, antibodies that can bind to btnl3 proteins and nucleic acids encoding btnl3 proteins are provided.
Amgen Inc.


06/18/15
20150166617 

Compositions and methods of treating alzheimer's disease


Disclosed herein are compositions of ghrh peptide antagonists, and methods to treat alzheimer's disease and other neurodegenerative disorders. Such compounds are useful for therapeutics, for protecting neuronal cells from cell-death and for promoting neuronal cell viability..
United States Of America, Represented By The Department Of Veterans Affairs


06/18/15
20150166606 

Peptide and peptidomimetic inhibitors


The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics..
Ra Pharmaceuticals, Inc.


06/18/15
20150166558 

Gonadotropin releasing hormone receptor antagonists, the preparation thereof and pharmaceutical composition comprising the same


Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as alzheimer disease.. .
Sk Chemicals Co., Ltd.


06/18/15
20150166538 

7-hydroxy-spiropipiperidine indolinyl antagonists of p2y1 receptor


The present invention provides compounds of formula (i): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of p2y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders..
Bristol-myers Squibb Company


06/18/15
20150166527 

Benzimidazole-proline derivatives


Wherein ar1, r1, r2, r3, r4a, r4b and (r5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (i), and especially to their use as orexin receptor antagonists.. .

06/18/15
20150166523 

Branched chain alkyl heteroaromatic ring derivative


A branched chain alkyl heteroaromatic ring derivative represented by formula (ia) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of the orexin (ox) receptor antagonist activity.. .
Taisho Pharmaceutical Co., Ltd.


06/18/15
20150166492 

Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof


Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (cma), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (rarα) in subjects in need thereof.. .
Albert Einstein College Of Medicine Of Yeshiva University


06/18/15
20150166490 

Mineralocorticoid receptor antagonists


As well as pharmaceutically acceptable salts thereof, that are potentially useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the formula i, to their possible use in the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula i..



Popular terms: [SEARCH]

Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3477

5063

1 - 1 - 107